These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 11514172)
61. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018 [TBL] [Abstract][Full Text] [Related]
62. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Franklin DS; Xiong Y Mol Biol Cell; 1996 Oct; 7(10):1587-99. PubMed ID: 8898364 [TBL] [Abstract][Full Text] [Related]
65. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Said TK; Moraes RC; Singh U; Kittrell FS; Medina D Cell Growth Differ; 2001 Jun; 12(6):285-95. PubMed ID: 11432803 [TBL] [Abstract][Full Text] [Related]
66. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines. Beattie JF; Breault GA; Ellston RP; Green S; Jewsbury PJ; Midgley CJ; Naven RT; Minshull CA; Pauptit RA; Tucker JA; Pease JE Bioorg Med Chem Lett; 2003 Sep; 13(18):2955-60. PubMed ID: 12941311 [TBL] [Abstract][Full Text] [Related]
67. Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4. Ding QM; Ko TC; Evers BM Am J Physiol; 1998 Nov; 275(5):C1193-200. PubMed ID: 9814966 [TBL] [Abstract][Full Text] [Related]
68. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345 [TBL] [Abstract][Full Text] [Related]
69. Modulation of cyclin-dependent kinase 4 by binding of magnesium (II) and manganese (II). Tian G; Kane LS; Holmes WD; Davis ST Biophys Chem; 2002 Jan; 95(1):79-90. PubMed ID: 11880175 [TBL] [Abstract][Full Text] [Related]
70. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. Kranenburg O; Scharnhorst V; Van der Eb AJ; Zantema A J Cell Biol; 1995 Oct; 131(1):227-34. PubMed ID: 7559779 [TBL] [Abstract][Full Text] [Related]
71. Aging impairs induction of cyclin-dependent kinases and down-regulation of p27 in mouse CD4(+) cells. Tamir A; Miller RA Cell Immunol; 1999 Nov; 198(1):11-20. PubMed ID: 10612647 [TBL] [Abstract][Full Text] [Related]
72. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. Nugiel DA; Vidwans A; Etzkorn AM; Rossi KA; Benfield PA; Burton CR; Cox S; Doleniak D; Seitz SP J Med Chem; 2002 Nov; 45(24):5224-32. PubMed ID: 12431050 [TBL] [Abstract][Full Text] [Related]
73. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. Thullberg M; Bartkova J; Khan S; Hansen K; Rönnstrand L; Lukas J; Strauss M; Bartek J FEBS Lett; 2000 Mar; 470(2):161-6. PubMed ID: 10734227 [TBL] [Abstract][Full Text] [Related]
76. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Breault GA; Ellston RP; Green S; James SR; Jewsbury PJ; Midgley CJ; Pauptit RA; Minshull CA; Tucker JA; Pease JE Bioorg Med Chem Lett; 2003 Sep; 13(18):2961-6. PubMed ID: 12941312 [TBL] [Abstract][Full Text] [Related]
77. An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states. Echalier A; Hole AJ; Lolli G; Endicott JA; Noble ME ACS Chem Biol; 2014 Jun; 9(6):1251-6. PubMed ID: 24669831 [TBL] [Abstract][Full Text] [Related]
78. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Keenan SM; Geyer JA; Welsh WJ; Prigge ST; Waters NC Comb Chem High Throughput Screen; 2005 Feb; 8(1):27-38. PubMed ID: 15720195 [TBL] [Abstract][Full Text] [Related]
79. CDK inhibition and cancer therapy. Garrett MD; Fattaey A Curr Opin Genet Dev; 1999 Feb; 9(1):104-11. PubMed ID: 10072351 [TBL] [Abstract][Full Text] [Related]